Theriva Biologics (TOVX)

Executive Summary

Theriva Biologics is a clinical-stage immuno-oncology company developing oncolytic virus therapeutics designed for systemic administration to selectively destroy solid tumors. Its lead candidate, VCN-01, is being advanced for metastatic pancreatic ductal adenocarcinoma (PDAC), a cancer with high unmet need. The company's technology aims to overcome the protective barriers surrounding tumors, enabling viral replication and tumor cell lysis. As a public company (NASDAQ: TOVX), Theriva has a market capitalization around $16 million, reflecting its early stage and high-risk profile. The company is focused on advancing VCN-01 through clinical trials, with potential to address a large patient population in PDAC and other solid tumors.

Upcoming Catalysts (preview)

• Q4 2026Interim data from Phase 2 trial of VCN-01 in pancreatic cancer40% success
• Q3 2026Orphan Drug Designation or Fast Track status from FDA for VCN-0150% success
• Q2 2026Equity financing or partnership deal to extend cash runway60% success